Recombinant factorIX(BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial-Reference-Cited by-同舟云学术

Recombinant factorIX(BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial

Author:

Urasinski T.¹,Stasyshyn O.²,Andreeva T.³,Rusen L.⁴,Perina F. G.⁵,Oh M. S.⁶,Chapman M.⁷,Pavlova B. G.⁷,Valenta‐Singer B.⁷,Abbuehl B. E.⁷

Affiliation:

1. Department of Paediatrics, Paediatric Haematology and Oncology Pomeranian Medical University in Szczecin Szczecin Poland

2. Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine Lviv Ukraine

3. Republican Center for Haemophilia Treatment St. Petersburg Russia

4. Prof. Dr. C. T. Nicolau National Institute for Transfusional Hematology Bucharest Romania

5. Regional Clinical Hospital Ekaterinburg Russia

6. Baxter BioScience Westlake Village CA USA

7. Baxter BioScience Vienna Austria

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

Reference37 articles.

4. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy;Rocca A;Blood Transfus,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献